Chronic Refractory Gout Market Size was valued ~USD 1,393 million in 2023 and is projected to grow rapidly with a significant CAGR by 2034

The Chronic Refractory Gout market size was valued ~USD 1,393 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Chronic Refractory Gout landscape.

In 2023, the United States represented the largest share of the Chronic Refractory Gout market, accounting for roughly 88% of the total market across the 7MM, significantly surpassing other key regions, including the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Within Europe, the United Kingdom recorded the highest market value at approximately USD 41 million in 2023, whereas France and Italy reported the lowest market values, each around USD 14 million. Meanwhile, Japan contributed only about 3% of the overall 7MM market size in 2023.

In 2024, gout affected more than 10 million people in the United States, underscoring the substantial impact of this chronic inflammatory disease nationwide. Within the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of chronic gout, with close to 170,000 patients, followed by France with over 73,000 cases. Projections indicate that the number of cases in the EU4 and the UK will continue to increase. Italy reported the fewest diagnosed prevalent cases in 2024, with approximately 70,000 individuals affected.

DelveInsight’s assessment indicates that in 2024, the 7MM reported over 400,000 diagnosed prevalent cases of Chronic Refractory Gout (CRG). This figure is projected to grow at a notable compound annual growth rate (CAGR) over the forecast timeframe of 2025–2034.

DelveInsight’s report, “Chronic Refractory Gout Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Chronic Refractory Gout landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Chronic Refractory Gout market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.
 
To Know in detail about the Chronic Refractory Gout market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Refractory Gout Market Forecast

Some of the key facts of the Chronic Refractory Gout Market Report:

• With the anticipated introduction of new therapies, including SEL-212, AR882, and SAP-001, among others, the Chronic Refractory Gout market is projected to experience significant growth in the coming years.
• Key Chronic Refractory Gout Companies: Swedish Orphan Biovitrum AB (Sobi), Selecta Biosciences, Atom Therapeutics, Amgen, Cartesian Therapeutics/Swedish Orphan Biovitrum (Sobi), Arthrosi Therapeutics, TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc, and others
• Key Chronic Refractory Gout Therapies: NASP (SEL-212), ABP-671, KRYSTEXXA (Pegloticase), SEL-212, AR882 TJC-0434, NC-2700, and others

Chronic Refractory Gout Overview

Chronic Refractory Gout is a severe form of gout in which patients continue to experience persistent symptoms such as painful, recurrent gout flares, joint inflammation, tophi (hard uric acid deposits), and progressive joint damage despite receiving standard urate-lowering therapies like allopurinol or febuxostat.

It occurs when uric acid levels remain uncontrolled or when treatment options are ineffective, poorly tolerated, or contraindicated. This condition significantly reduces quality of life and often requires advanced therapies, including biologics or novel uric acid-lowering agents, to manage symptoms and prevent complications.

Get a Free sample for the Chronic Refractory Gout Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-refractory-gout-market

Key Trends in Chronic Refractory Gout Therapeutics Market:

• Shift Toward Biologic and Targeted Therapies: Increasing adoption of biologics and novel targeted agents such as IL-1 inhibitors and uric acid–lowering biologics is reshaping the treatment landscape for severe gout cases unresponsive to conventional therapies.
• Emerging Pipeline Drugs Showing Strong Potential: Multiple late-stage candidates, including SEL-212, AR882, and SAP-001, are demonstrating promising clinical outcomes, driving expectations for improved long-term disease control and reduced treatment resistance.
• Rising Disease Awareness and Earlier Diagnosis: Greater clinical recognition of poorly controlled gout and associated comorbidities is supporting increased diagnosis and specialist referrals, thereby expanding the treatable patient population.
• Growing Emphasis on Personalized and Combination Therapy Approaches: Treatment strategies are moving toward tailored regimens and combination therapies to optimize urate reduction and manage complex refractory cases more effectively.
  Increasing Healthcare Costs Driving Demand for Cost-Effective Solutions: Elevated economic burden associated with treatment failures and hospitalizations is prompting interest in therapies that deliver sustained efficacy and reduce overall healthcare expenditure.

Chronic Refractory Gout Epidemiology

The Chronic Refractory Gout epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Refractory Gout Epidemiology Segmentation:

The Chronic Refractory Gout market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Gout in the 7MM
• Total Diagnosed Prevalent Cases of Chronic Gout in the 7MM
• Total Diagnosed Prevalent Cases of CRG in the 7MM
• Treated Cases of CRG in the 7MM

Download the report to understand which factors are driving Chronic Refractory Gout epidemiology trends @ Chronic Refractory Gout Epidemiology Forecast

Recent Development In The Chronic Refractory Gout Treatment Landscape:

• In March 2025, Shanton Pharma, a clinical-stage biotechnology company focused on innovative gout therapies, announced topline results from its Phase 2b study involving patients with refractory gout. The investigational drug, SAP-001, features a first-in-class mechanism of action that targets a unique kidney transporter.
• In August 2024, AR882 was granted fast-track designation by the FDA for the treatment of gout.

Chronic Refractory Gout Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Gout market or expected to get launched during the study period. The analysis covers Chronic Refractory Gout market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Refractory Gout Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Refractory Gout Therapies and Key Companies

• NASP (SEL-212): Swedish Orphan Biovitrum AB (Sobi)/ Selecta Biosciences
• ABP-671: Atom Therapeutics
• KRYSTEXXA (Pegloticase): Amgen
• SEL-212: Cartesian Therapeutics/Swedish Orphan Biovitrum (Sobi)
• AR882: Arthrosi Therapeutics
• SEL-212: Selecta Biosciences, Inc
• Pegloticase: Amgen
• TJC-0434: TaiwanJ Pharmaceuticals
• NC-2700: Nippon Chemiphar
• Research Program: HemoShear Horizon Therapeutics plc
• NC-2500: Nippon Chemiphar
• PRX-115: Protalix BioTherapeutics
• HZN-457: Horizon Therapeutics plc

Discover more about therapies set to grab major Chronic Refractory Gout market share @ Chronic Refractory Gout Treatment Landscape

Chronic Refractory Gout Market Drivers

• Rising prevalence of gout and hyperuricemia globally, increasing demand for effective treatments.
• Growing number of patients unresponsive to standard therapies, driving the need for novel therapies.
• Advancements in biologics and urate-lowering agents, improving treatment outcomes for refractory cases.
• Increasing awareness among clinicians and patients about chronic gout management.
• Favorable reimbursement policies and orphan drug incentives in several regions supporting market growth.

Chronic Refractory Gout Market Barriers

• High cost of novel therapies and biologics, limiting patient access in some regions.
• Safety and tolerability concerns with long-term use of advanced treatments.
• Limited awareness or diagnosis of refractory gout, leading to under-treatment.
• Small patient population for refractory cases, restricting large-scale clinical trials.
• Challenges in treatment adherence and monitoring, affecting real-world outcomes.

Scope of the Chronic Refractory Gout Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Refractory Gout Companies: Swedish Orphan Biovitrum AB (Sobi), Selecta Biosciences, Atom Therapeutics, Amgen, Cartesian Therapeutics/Swedish Orphan Biovitrum (Sobi), Arthrosi Therapeutics, TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc, and others
• Key Chronic Refractory Gout Therapies: NASP (SEL-212), ABP-671, KRYSTEXXA (Pegloticase), SEL-212, AR882 TJC-0434, NC-2700, and others
• Chronic Refractory Gout Therapeutic Assessment: Chronic Refractory Gout current marketed and Chronic Refractory Gout emerging therapies
• Chronic Refractory Gout Market Dynamics: Chronic Refractory Gout market drivers and Chronic Refractory Gout market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Refractory Gout Unmet Needs, KOL’s views, Analyst’s views, Chronic Refractory Gout Market Access and Reimbursement

To know more about Chronic Refractory Gout companies working in the treatment market, visit @ Chronic Refractory Gout Clinical Trials and Therapeutic Assessment

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.